Independent business analysis - markets, industries, and the economic patterns shaping how we live.
Pharmaceutical industry political spending remains among the largest sector-specific lobbying in US and European politics. What the money actually accomplishes, how policy actually responds, and what the returns to lobbying investment tell us about political economy.
European pharmacy consolidation over the past decade has substantially reshaped how consumers access pharmaceutical products. What the consolidation actually looks like across major European markets, how it affects pricing, and what the implications are for cross-border pharmaceutical access.
Platform consolidation across e-commerce, media distribution, and various consumer markets has reshaped how consumers access products and information. What the actual economic effects have been beyond antitrust arguments, and what alternative distribution channels have emerged.
The direct-to-consumer telehealth pharmacy model has generated substantial commercial success. What these companies actually sell — beyond the medications they distribute — and how the economics compare to alternative pharmaceutical access approaches.
The pharmaceutical price differential between markets is not primarily about drug quality — it's about market structure, patent geography, and regulatory capture. What the sildenafil price landscape actually reveals about global pharmaceutical economics.